title: Cardiac electrophysiologic and antiarrhythmic actions of tedisamil.
abstract: The Class III electrophysiologic and antiarrhythmic actions of the bradycardic agent tedisamil were assessed in vitro and in vivo. In ferret isolated right ventricular papillary muscles, tedisamil increased effective refractory period (ERP) in a concentration-dependent manner, with a 25% ERP increase achieved with 3.0 microM tedisamil, and a 133.4% +/- 28.8% increase in ERP achieved at the high 100 microM concentration tested. In anesthetized dogs, the cumulative i.v. administration of tedisamil significantly increased ventricular relative refractory period (VRRP) and ventricular effective refractory period (VERP) as well as electrocardiographic QTc intervals (100-1000 micrograms/kg i.v.). A 20msec increase in VRRP was achieved with 45.0 micrograms/kg i.v. tedisamil, and a 56.1 +/- 9.8 msec (40.1% +/- 8.1%) increase in VRRP was achieved at the highest dose tested (1000 micrograms/kg i.v.). In the same dosage range in anesthetized dogs, tedisamil produced significant hemodynamic effects, including reduction in HR (100-1000 micrograms/kg i.v.) and elevations in mean arterial pressure (1000 micrograms/kg i.v.), left ventricular developed pressure (1000 micrograms/kg i.v.) and the maximum rate of LV pressure development (100-1000 micrograms/kg i.v.). In anesthetized dogs studied chronically (8.2 +/- 0.6 days) after anterior myocardial infarction, tedisamil suppressed programmed stimulation-induced ventricular tachyarrhythmias (8/10, 80% suppression at 100-1000 micrograms/kg i.v.) and reduced the incidence of lethal ischemic arrhythmias developing in response to acute posterolateral myocardial ischemia (arrhythmic mortality 5/10, 50% tedisamil vs. 34/40, 85% vehicle control cohort; P = .027). The latter findings suggest that tedisamil might be useful in the prevention of malignant ventricular arrhythmias in the setting of myocardial ischemic injury.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Wallace
authors.forename: R F
authors.initials: RF
authors.lastname: Stupienski
authors.forename: E P
authors.initials: EP
authors.lastname: Baskin
authors.forename: S D
authors.initials: SD
authors.lastname: Appleby
authors.forename: T
authors.initials: T
authors.lastname: Kothstein
authors.forename: J R
authors.initials: JR
authors.lastname: Gehret
authors.forename: S W
authors.initials: SW
authors.lastname: King
authors.forename: D C
authors.initials: DC
authors.lastname: Remy
authors.forename: J J
authors.initials: JJ
authors.lastname: Lynch
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes / Q000494:pharmacology*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D005289:Ferrets; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D017202:Myocardial Ischemia / Q000503:physiopathology; D010210:Papillary Muscles / Q000187:drug effects / Q000502:physiology; D015221:Potassium Channels / Q000187:drug effects; D012032:Refractory Period, Electrophysiological / Q000187:drug effects
chemical_list: D000889:Anti-Arrhythmia Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes; D015221:Potassium Channels; C059921:tedisamil